Affiris (Vaccine Candidate PD01) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Affiris (Vaccine Candidate PD01) General Information
Description
Anti-alpha-synuclein programs targeting neurodegenerative diseases based in Vienna, Austria.
Contact Information
Corporate Office
- Karl-Farkas-Gasse 22
- Vienna, 1030
- Austria
Corporate Office
- Karl-Farkas-Gasse 22
- Vienna, 1030
- Austria
Affiris (Vaccine Candidate PD01) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Affiris (Vaccine Candidate PD01) FAQs
-
Where is Affiris (Vaccine Candidate PD01) headquartered?
Affiris (Vaccine Candidate PD01) is headquartered in Vienna, Austria.
-
What industry is Affiris (Vaccine Candidate PD01) in?
Affiris (Vaccine Candidate PD01)’s primary industry is Buildings and Property.
-
Is Affiris (Vaccine Candidate PD01) a private or public company?
Affiris (Vaccine Candidate PD01) is a Private company.
-
What is the current valuation of Affiris (Vaccine Candidate PD01)?
The current valuation of Affiris (Vaccine Candidate PD01) is .
-
What is Affiris (Vaccine Candidate PD01)’s current revenue?
The current revenue for Affiris (Vaccine Candidate PD01) is .
-
When was Affiris (Vaccine Candidate PD01) acquired?
Affiris (Vaccine Candidate PD01) was acquired on 27-Jul-2021.
-
Who acquired Affiris (Vaccine Candidate PD01)?
Affiris (Vaccine Candidate PD01) was acquired by AC Immune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process